Updated just now · Live
Stock analysis, price data, and AI-powered insights for Allogene Therapeutics Inc (ALLO).
Allogene Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ALLO.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ALLO Stock Intelligence Report. [stoxpulse.com/stocks/allo]
Disclaimer: The information on this page about Allogene Therapeutics Inc (ALLO) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Allogene Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Allogene Therapeutics Receive South Korea, Austral...
7h ago
Allogene Therapeutics Expands Pivotal Phase 2 ALPH...
7h ago
StoxPulse AI results for ALLO: Pulse Score 54/100. Primary sentiment trends from 14 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$801.7M
P/E Ratio
—
EPS
$-0.19
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Allogene Therapeutics Receive South Korea, Australia Clearance To Expand Its Pivotal Phase 2 ALPHA3 Trial Of Cemacabtagene Ansegedleucel To Treat Patients With Large B-Cell Lymphoma
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Allogene Therapeutics announces closing of $200.4 million public offering of common stock
Thursday's session: gap up and gap down stocks
JP Morgan Upgrades Allogene Therapeutics to Neutral
Allogene Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and lowered its price target from $12 to $11.
Aehr Test Systems, CareDx, Okta And Other Big Stocks Moving Higher On Thursday